These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 29050070)

  • 41. [Loss of heterozygosity of chromosome 1p/19q and p53 protein expression in oligodendroglioma].
    Xiong J; Liu Y; Li C; Zhu JJ; Ye ZR; Mao Y; Wang Y
    Zhonghua Bing Li Xue Za Zhi; 2009 Jul; 38(7):445-50. PubMed ID: 19781190
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The Correlation Between 1p/19q Codeletion, IDH1 Mutation, p53 Overexpression and Their Prognostic Roles in 41 Turkish Anaplastic Oligodendroglioma Patients.
    Hacisalihoglu P; Kucukodaci Z; Gundogdu G; Bilgic B
    Turk Neurosurg; 2017; 27(5):682-689. PubMed ID: 27651340
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Treatment of anaplastic glioma.
    Wick W; Wiestler B; Platten M
    Cancer Treat Res; 2015; 163():89-101. PubMed ID: 25468227
    [TBL] [Abstract][Full Text] [Related]  

  • 44. In vivo molecular profiling of human glioma using diffusion kurtosis imaging.
    Hempel JM; Bisdas S; Schittenhelm J; Brendle C; Bender B; Wassmann H; Skardelly M; Tabatabai G; Vega SC; Ernemann U; Klose U
    J Neurooncol; 2017 Jan; 131(1):93-101. PubMed ID: 27604789
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Utility of in situ demonstration of 1p loss and p53 overexpression in pathologic diagnosis of oligodendroglial tumors.
    Hirose T; Ishizawa K; Shimada S
    Neuropathology; 2010 Dec; 30(6):586-96. PubMed ID: 20408960
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical impact of molecular biomarkers in gliomas.
    Siegal T
    J Clin Neurosci; 2015 Mar; 22(3):437-44. PubMed ID: 25533211
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Molecular Aberrations Associated with Seizure Control in Diffuse Astrocytic and Oligodendroglial Tumors.
    Suzuki H; Mikuni N; Sugita S; Aoyama T; Yokoyama R; Suzuki Y; Enatsu R; Akiyama Y; Mikami T; Wanibuchi M; Hasegawa T
    Neurol Med Chir (Tokyo); 2020 Mar; 60(3):147-155. PubMed ID: 32009124
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A simple algorithmic approach using histology and immunohistochemistry for the current classification of adult diffuse glioma in a resource-limited set-up.
    Rajeswarie RT; Rao S; Nandeesh BN; Yasha TC; Santosh V
    J Clin Pathol; 2018 Apr; 71(4):323-329. PubMed ID: 28801347
    [TBL] [Abstract][Full Text] [Related]  

  • 49. New Molecular Considerations for Glioma: IDH, ATRX, BRAF, TERT, H3 K27M.
    Karsy M; Guan J; Cohen AL; Jensen RL; Colman H
    Curr Neurol Neurosci Rep; 2017 Feb; 17(2):19. PubMed ID: 28271343
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1/2 mutation without the 1p/19q co-deletion.
    Kawaguchi T; Sonoda Y; Shibahara I; Saito R; Kanamori M; Kumabe T; Tominaga T
    J Neurooncol; 2016 Sep; 129(3):505-514. PubMed ID: 27401154
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Somatostatin receptor 2A in gliomas: Association with oligodendrogliomas and favourable outcome.
    Kiviniemi A; Gardberg M; Kivinen K; Posti JP; Vuorinen V; Sipilä J; Rahi M; Sankinen M; Minn H
    Oncotarget; 2017 Jul; 8(30):49123-49132. PubMed ID: 28467778
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Diagnostic and prognostic roles of loss of CIC protein expression in oligodendroglial tumors].
    Liu CC; Zhang LY; Wang LM; Wang DD; Fu YJ; Cai YN; Lu DH; Piao YS
    Zhonghua Bing Li Xue Za Zhi; 2017 Oct; 46(10):679-683. PubMed ID: 29050068
    [No Abstract]   [Full Text] [Related]  

  • 53. Clinical evaluation of a dedicated next generation sequencing panel for routine glioma diagnostics.
    Synhaeve NE; van den Bent MJ; French PJ; Dinjens WNM; Atmodimedjo PN; Kros JM; Verdijk R; Dirven CMF; Dubbink HJ
    Acta Neuropathol Commun; 2018 Nov; 6(1):126. PubMed ID: 30470264
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Histomolecular diagnosis of glial and glioneuronal tumours].
    Métais A; Rousseau A
    Ann Pathol; 2021 Apr; 41(2):137-153. PubMed ID: 33712303
    [TBL] [Abstract][Full Text] [Related]  

  • 55. An immune signature to predict the prognosis of
    Cao W; Sun P; Luo S; Zeng Z; Xiao C; Yu W; Lei S
    Aging (Albany NY); 2023 Oct; 15(19):10453-10472. PubMed ID: 37812190
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A nomogram strategy for identifying the subclassification of IDH mutation and ATRX expression loss in lower-grade gliomas.
    Wu S; Zhang X; Rui W; Sheng Y; Yu Y; Zhang Y; Yao Z; Qiu T; Ren Y
    Eur Radiol; 2022 May; 32(5):3187-3198. PubMed ID: 35133485
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A surgical strategy for lower grade gliomas using intraoperative molecular diagnosis.
    Koriyama S; Nitta M; Kobayashi T; Muragaki Y; Suzuki A; Maruyama T; Komori T; Masui K; Saito T; Yasuda T; Hosono J; Okamoto S; Shioyama T; Yamatani H; Kawamata T
    Brain Tumor Pathol; 2018 Jul; 35(3):159-167. PubMed ID: 29980868
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Significance of H3K27M mutation with specific histomorphological features and associated molecular alterations in pediatric high-grade glial tumors.
    Bozkurt SU; Dagcinar A; Tanrikulu B; Comunoglu N; Meydan BC; Ozek M; Oz B
    Childs Nerv Syst; 2018 Jan; 34(1):107-116. PubMed ID: 29063957
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Immunohistochemical Analysis of ATRX, IDH1 and p53 in Glioblastoma and Their Correlations with Patient Survival.
    Chaurasia A; Park SH; Seo JW; Park CK
    J Korean Med Sci; 2016 Aug; 31(8):1208-14. PubMed ID: 27478330
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Grade II and III Oligodendroglioma and Astrocytoma.
    van den Bent MJ; Chang SM
    Neurol Clin; 2018 Aug; 36(3):467-484. PubMed ID: 30072066
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.